Literature DB >> 32361749

Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model.

Iain J Abbott1,2, Elke van Gorp2, Rixt A Wijma2,3, Jordy Dekker2, Peter D Croughs2, Joseph Meletiadis4, Johan W Mouton2, Anton Y Peleg1,5.   

Abstract

OBJECTIVES: We used a dynamic bladder infection in vitro model with synthetic human urine (SHU) to examine fosfomycin exposures to effectively kill, or prevent emergence of resistance, among Pseudomonas aeruginosa isolates.
METHODS: Dynamic urinary fosfomycin concentrations after 3 g oral fosfomycin were simulated, comparing single and multiple (daily for 7 days) doses. Pharmacodynamic response of 16 P. aeruginosa (MIC range 1 to >1024 mg/L) were examined. Baseline disc diffusion susceptibility, broth microdilution MIC and detection of heteroresistance were assessed. Pathogen kill and emergence of resistance over 72 h following a single dose, and over 216 h following daily dosing for 7 days, were investigated. The fAUC0-24/MIC associated with stasis and 1, 2 and 3 log10 kill were determined.
RESULTS: Pre-exposure high-level resistant (HLR) subpopulations were detected in 11/16 isolates after drug-free incubation in the bladder infection model. Five of 16 isolates had >2 log10 kill after single dose, reducing to 2/16 after seven doses. Post-exposure HLR amplification occurred in 8/16 isolates following a single dose and in 11/16 isolates after seven doses. Baseline MIC ≥8 mg/L with an HLR subpopulation predicted post-exposure emergence of resistance following the multiple doses. A PK/PD target of fAUC0-24/MIC >5000 was associated with 3 log10 kill at 72 h and 7 day-stasis.
CONCLUSIONS: Simulated treatment of P. aeruginosa urinary tract infections with oral fosfomycin was ineffective, despite exposure to high urinary concentrations and repeated daily doses for 7 days. Emergence of resistance was observed in the majority of isolates and worsened following prolonged therapy. Detection of a baseline resistant subpopulation predicted treatment failure.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32361749     DOI: 10.1093/jac/dkaa127

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Performance of Four Fosfomycin Susceptibility Testing Methods against an International Collection of Clinical Pseudomonas aeruginosa Isolates.

Authors:  Elizabeth C Smith; Hunter V Brigman; Jadyn C Anderson; Christopher L Emery; Tiffany E Bias; Phillip J Bergen; Cornelia B Landersdorfer; Elizabeth B Hirsch
Journal:  J Clin Microbiol       Date:  2020-09-22       Impact factor: 5.948

Review 2.  Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and Enterobacterales.

Authors:  Dina Zheng; Phillip J Bergen; Cornelia B Landersdorfer; Elizabeth B Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2021-11-22       Impact factor: 5.938

Review 3.  The Emergence and Dissemination of Multidrug Resistant Pseudomonas aeruginosa in Lebanon: Current Status and Challenges during the Economic Crisis.

Authors:  Ahmad Ayman Dabbousi; Fouad Dabboussi; Monzer Hamze; Marwan Osman; Issmat I Kassem
Journal:  Antibiotics (Basel)       Date:  2022-05-19

4.  Diagnostic value of different urine tests for urinary tract infection: a systematic review and meta-analysis.

Authors:  Rong Xie; Xinli Li; Guangquan Li; Rong Fu
Journal:  Transl Androl Urol       Date:  2022-03

5.  Antibiofilm property and multiple action of peptide PEW300 against Pseudomonas aeruginosa.

Authors:  Meng Wang; Zifeng Deng; Yanmei Li; Keyong Xu; Yi Ma; Shang-Tian Yang; Jufang Wang
Journal:  Front Microbiol       Date:  2022-07-29       Impact factor: 6.064

Review 6.  Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis; Achilleas Gikas
Journal:  Infection       Date:  2020-09-01       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.